TEVA : Summary for Teva Pharmaceutical Industries - Yahoo Finance

U.S. Markets close in 2 hrs 42 mins

Teva Pharmaceutical Industries Limited (TEVA)


NYSE - NYSE Real Time Price. Currency in USD
Add to watchlist
34.96-0.45 (-1.27%)
As of 1:17PM EST. Market open.
People also watch
MYLNVSGILDAMGNABT
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close35.41
Open35.25
Bid0.00 x
Ask0.00 x
Day's Range34.86 - 35.48
52 Week Range31.90 - 59.35
Volume3,500,862
Avg. Volume11,033,508
Market Cap35.63B
Beta0.62
PE Ratio (TTM)499.43
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield1.36 (3.84%)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • 24/7 Wall St.4 hours ago

    Why Short Sellers Are Making a Massive Bet in Major Pharma

    Judging by this report, short sellers are making a tremendous bet against Trump’s plan to reform the health care sector.

  • Reuters5 hours ago

    FDA to expedite review of Teva drug for movement disorder

    Israel-based Teva Pharmaceutical Industries said on Tuesday the U.S. Food and Drug Administration (FDA) has granted "priority review" for its SD-809 drug to treat tardive dyskinesia with a target date for approval by Aug. 30. A priority, or expedited, review allows for a faster evaluation of drug applications. Tardive dyskinesia, a condition for which there are no approved therapies in the United States, is a disorder characterised by repetitive and uncontrollable movements.

  • Business Wire5 hours ago

    Teva Announces Priority Review Granted by FDA for SD-809 for Treatment of Tardive Dyskinesia

    Teva Pharmaceutical Industries Ltd. today announced the U.S. Food and Drug Administration has accepted the New Drug Application and granted Priority Review for SD-809 for the treatment of tardive dyskinesia .